VAX014 is a first-in-class recombinant bacterial minicell-based oncolytic immunotherapy.
Vaxiion will soon initiate a multi-center, open label Phase 1 dose escalation study to evaluate the safety, tolerability, and initial antitumor activity in both treated and untreated lesions following intralesional administration of VAX014.
The upcoming Phase 1 study is not restricted by indication, allowing for assessment of safety and activity of VAX014 across multiple injectable solid tumor types.
Intralesional administration of VAX014 in preclinical models utilizing immunologically "cold" and "immune excluded" solid tumors consistently demonstrates durable, immune-dependent clearance of treated tumors.
These studies have also demonstrated systemic immune-dependent activity against untreated secondary tumors (abscopal effect) coinciding with development of antitumor immunologic memory.
VAX014 is the first clinical product candidate generated from Vaxiion's proprietary recombinant bacterial-minicell delivery platform.
An ongoing Phase 1 study of VAX014 for the intravesical treatment of non-muscle invasive bladder cancer has demonstrated VAX014 to be safe and well tolerated with early indications of antitumor activity.
Vaxiion Therapeutics is a clinical stage San Diego-based biotechnology company. Leveraging its closely related pair of proprietary first-in-class bacterial minicell-based delivery platforms, Vaxiion is developing and advancing novel, next generation oncology products.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval